These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 30947287)
1. Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells. Willms A; Schittek H; Rahn S; Sosna J; Mert U; Adam D; Trauzold A PLoS One; 2019; 14(4):e0214847. PubMed ID: 30947287 [TBL] [Abstract][Full Text] [Related]
2. Activation of p38 MAPK by damnacanthal mediates apoptosis in SKHep 1 cells through the DR5/TRAIL and TNFR1/TNF-α and p53 pathways. Lin FL; Hsu JL; Chou CH; Wu WJ; Chang CI; Liu HJ Eur J Pharmacol; 2011 Jan; 650(1):120-9. PubMed ID: 20951126 [TBL] [Abstract][Full Text] [Related]
3. Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species- and ERK-dependent up-regulation of death receptors, p53, and Bax. Gupta SC; Reuter S; Phromnoi K; Park B; Hema PS; Nair M; Aggarwal BB J Biol Chem; 2011 Jan; 286(2):1134-46. PubMed ID: 21078664 [TBL] [Abstract][Full Text] [Related]
4. Urokinase-type plasminogen activator receptor regulates apoptotic sensitivity of colon cancer HCT116 cell line to TRAIL via JNK-p53 pathway. Liu X; Qiu F; Liu Z; Lan Y; Wang K; Zhou PK; Wang Y; Hua ZC Apoptosis; 2014 Oct; 19(10):1532-44. PubMed ID: 25113506 [TBL] [Abstract][Full Text] [Related]
5. Combinatorial treatment with anacardic acid followed by TRAIL augments induction of apoptosis in TRAIL resistant cancer cells by the regulation of p53, MAPK and NFκβ pathways. Harsha Raj M; Yashaswini B; Rössler J; Salimath BP Apoptosis; 2016 May; 21(5):578-93. PubMed ID: 26921178 [TBL] [Abstract][Full Text] [Related]
6. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Wang S; El-Deiry WS Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15095-100. PubMed ID: 14645705 [TBL] [Abstract][Full Text] [Related]
7. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5. Lemke J; Noack A; Adam D; Tchikov V; Bertsch U; Röder C; Schütze S; Wajant H; Kalthoff H; Trauzold A J Mol Med (Berl); 2010 Jul; 88(7):729-40. PubMed ID: 20354842 [TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 sensitizes TNF-α and TRAIL/Apo2L dependent cell death through upregulation of death receptors in human cancer cells. Sano E; Kazaana A; Tadakuma H; Takei T; Yoshimura S; Hanashima Y; Ozawa Y; Yoshino A; Suzuki Y; Ueda T Biochim Biophys Acta Mol Cell Res; 2021 Jun; 1868(7):119037. PubMed ID: 33839168 [TBL] [Abstract][Full Text] [Related]
9. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L). Ravi R; Bedi A Cancer Res; 2002 Mar; 62(6):1583-7. PubMed ID: 11912124 [TBL] [Abstract][Full Text] [Related]
10. Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo. Zopf S; Neureiter D; Bouralexis S; Abt T; Glaser KB; Okamoto K; Ganslmayer M; Hahn EG; Herold C; Ocker M Int J Oncol; 2007 Dec; 31(6):1391-402. PubMed ID: 17982666 [TBL] [Abstract][Full Text] [Related]
11. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Ravi R; Bedi A Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014 [TBL] [Abstract][Full Text] [Related]
12. Bax is essential for death receptor-mediated apoptosis in human colon cancer cells. Zhu S; Li T; Tan J; Yan X; Zhang D; Zheng C; Chen Y; Xiang Z; Cui H Cancer Biother Radiopharm; 2012 Nov; 27(9):577-81. PubMed ID: 23113596 [TBL] [Abstract][Full Text] [Related]
13. Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4. Bychkov ML; Gasparian ME; Dolgikh DA; Kirpichnikov MP PLoS One; 2014; 9(10):e109756. PubMed ID: 25310712 [TBL] [Abstract][Full Text] [Related]
14. Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation. Chen L; Meng Y; Sun Q; Zhang Z; Guo X; Sheng X; Tai G; Cheng H; Zhou Y Cell Death Dis; 2016 Aug; 7(8):e2334. PubMed ID: 27512955 [TBL] [Abstract][Full Text] [Related]
15. Death receptor 5 is activated by fucosylation in colon cancer cells. Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515 [TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Nawrocki ST; Carew JS; Douglas L; Cleveland JL; Humphreys R; Houghton JA Cancer Res; 2007 Jul; 67(14):6987-94. PubMed ID: 17638911 [TBL] [Abstract][Full Text] [Related]
17. TRAIL-induced apoptosis is enhanced by heat shock protein 70 expression. Clemons NJ; Anderson RL Cell Stress Chaperones; 2006; 11(4):343-55. PubMed ID: 17278883 [TBL] [Abstract][Full Text] [Related]
18. Platinum(IV) complex LA-12 exerts higher ability than cisplatin to enhance TRAIL-induced cancer cell apoptosis via stimulation of mitochondrial pathway. Jelínková I; Šafaříková B; Vondálová Blanářová O; Skender B; Hofmanová J; Sova P; Moyer MP; Kozubík A; Kolář Z; Ehrmann J; Hyršlová Vaculová A Biochem Pharmacol; 2014 Dec; 92(3):415-24. PubMed ID: 25285768 [TBL] [Abstract][Full Text] [Related]
19. Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation. Park EJ; Choi KS; Yoo YH; Kwon TK Anticancer Drugs; 2013 Mar; 24(3):260-9. PubMed ID: 23187459 [TBL] [Abstract][Full Text] [Related]
20. Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells. Hori T; Kondo T; Kanamori M; Tabuchi Y; Ogawa R; Zhao QL; Ahmed K; Yasuda T; Seki S; Suzuki K; Kimura T Cancer Lett; 2010 Jan; 287(1):98-108. PubMed ID: 19577358 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]